Clear All
777 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
Vorasidenib Voranigo 10mg,40mg Chemotherapy IDH Inhibitor IDH1, IDH2 Yes 2024 In Use
NA Dacomitinib Vizimpro 15mg, 30mg, 45mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2018 In Use
NA Carmustine wafer Gliadel 7.7mg Chemotherapy Alkylating Agent Nitrosourea No 2012 In Use
NA idelalisib Zydelig 150 mg Chemotherapy Enzyme Inhibitor PI3K Yes 2014 In Use
NA Enasidenib mesylate Idhifa 100 mg Chemotherapy Enzyme Inhibitor IDH2 Yes 2017 In Use
NA Alpelisib Piqray 200mg Chemotherapy Enzyme Inhibitor PI3K Yes 2019 In Use
NA Pirtobrutinib Jaypirca Multiple Chemotherapy Tyrosine Kinase Inhibitor BTK Yes 2023 In Use
N/A Taletrectinib IBTROZI 272mg Chemotherapy Tyrosine Kinase Inhibitor ROS1, TRKA, TRKB, TRKC Yes 2025 In Use
NA Nilotinib Tasigna 200 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2007 In Use
NA Vandetanib Caprelsa 300 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, EGFR Yes 2011 In Use
NA Alpelisib Piqray 150mg Chemotherapy Enzyme Inhibitor PI3K Yes 2019 In Use
NA Avapritinib Ayvakit 200mg Chemotherapy Tyrosine Kinase Inhibitor PDGFR, KIT, CSFR1 Yes 2020 In Use
NA Estrogens, Esterified Covaryx, Covaryx H.S., Menest, Ogen, Ortho-Est 2.5 mg Hormonal Therapy Estrogen Yes 1977 In Use
NA Erlotinib Tarceva 25 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2004 In Use
Nirogacestat Ogsiveo 50mg, 100mg, 150mg Ancillary Therapy Miscellaneous Agent Ɣ Secretase Inhibitor Yes 2023 In Use
NA ixazomib Ninlaro 2.3 mg Chemotherapy Proteasome Inhibitor 20S Yes 2015 In Use
NA Abemaciclib Verzenio 50 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2017 In Use
NA Erlotinib Tarceva 150 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2004 In Use
N/A Avutometinib potassium and defactinib hydrochloride AVMAPKI FAKZYNJA CO-PACK 0.8mg and 200mg Chemotherapy MEK Inhibitor, Tyrosine Kinase Inhibitor MEK1/2, ERK1/2, KRAS Yes 2025 In Use
NA Fedratinib Hydrochloride Inrebic 100mg Chemotherapy Enzyme Inhibitor JAK2, FLT3 Yes 2019 In Use
NA Aprepitant Emend 80 mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Yes 2003 In Use
NA Anagrelide Agrylin 0.5mg Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Yes 1997 In Use
NA Avapritinib Ayvakit 25mg Chemotherapy Tyrosine Kinase Inhibitor PDGFR, KIT, CSFR1 Yes 2020 In Use
Asciminib Scemblix 20mg,40mg Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Yes 2021 In Use
NA Imiquimod Aldara 5% Immunotherapy Immunomodulator Retinoic Acid Derivative No 1997 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.